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Breast and ovarian cancers belong to the most common
malignancies diagnosed in women. The major inherited
susceptibilities to breast and ovarian cancers are germ-
line mutations in either BRCA1 or BRCA2 which how-
ever, explain only small number of breast and ovarian
cancer cases. Data suggest that majority breast and ovar-
ian cancers are caused by low or moderate penetrance
gene mutations. Identification of such mutations pro-
vides cancer risk assessment and will help in prophylac-
tic, early diagnosis and treatment.
In 2005 three international multidisciplinary consortia
have been initiated: Breast Cancer Association Con-
sortium (BCAC), Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) and Ovarian Cancer
Association Consortium (OCAC) which are forums of
investigators from centers over the world, including
International Hereditary Cancer Center in Szczecin. The
aim of these consortia’s is to combine data from many
studies, to provide a reliable assessment of the breast
and ovarian cancer risks associated with different
genetic and environmental factors, and to identify
potential modifiers of cancer risk in carriers of BRCA1
and BRCA2 mutation.
BCAC includes 54 centers (table 1) over the world
and focuses on identification of genes associated with
breast cancer risk.
Currently, BCAC database includs demographic, clini-
cal and epidemiological data from 73,000 breast cancer
patients and 80,000 unaffected women. Up to now, 125
genetic alterations (SNPs) localized in different genes
have been examined. These SNPs have been selected
based on its positive association with breast cancer risk
detected in preliminary analyses or Genome-Wide Asso-
ciation Study (GWAS). Results have been presented in
12 manuscripts published in high impact journals, e.g. J
Natl Cancer Inst, Nature and Nat Genet (http://www.srl.
cam.ac.uk/consortia/bcac/pubs/pubs.html).
Ten SNPs have been found to be associated with
breast cancer risk overall or by clinical and pathological
characteristics (table 2).
CIMBA database contains demographic, clinical and
epidemiological data from 15,700 BRCA1 and 8,600
BRCA2, mutation carriers including 12,700 breast can-
cer patients, 2,500 ovarian cancer patients and 9,100
unaffected patients from 42 centers over the world
(table 3).
Results have been presented in 9 manuscripts pub-
lished in high impact journals, e.g. Am. J Hum Genet,
Hum Mol Genet (http://www.srl.cam.ac.uk/consortia/
cimba/pubs/pubs.html).
Six SNPs have been found to be associated with breast
cancer risk (table 4).
OCAC includes 24 centers over the world and focuses
on identification of genes that may be related to the risk
of ovarian cancer (table 5).
Currently, OCAC database includs demographic, clini-
cal and epidemiological data from 22,000 ovarian cancer
patients and 18,000 unaffected women. Several genetic
alterations (SNPs) localized in different genes have been
examined. Results have been presented in 13 manu-
scripts published in high impact journals, e.g. Nat
Genet, Cancer Res, In J Cancer (http://www.srl.cam.ac.
uk/consortia/ocac/pubs/pubs.html).
Seven SNPs have been found to be associated with
ovarian cancer risk overall or by clinical and pathologi-
cal characteristics (table 6). International Hereditary Cancer Center, Pomeranian Medical University,
Szczecin, Poland
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Name Acronym Country
Australian Breast Cancer Family Study ABCFS Australia
Amsterdam Breast Cancer Study ABCS Netherlands
Australian Breast Cancer Tissue Bank ABCTB Australia
Asia Cancer Program ACP Thailand
Bavarian Breast Cancer Cases and Controls BBCC Germany
British Breast Cancer Study BBCS UK
Breast Cancer In Galway Genetic Study BIGGS Ireland
Breast Cancer Study of the University Clinic Heidelberg BSUCH Germany
CECILE Breast Cancer Study CECILE France
Copenhagen General Population Study CGPS Denmark
Spanish National Cancer Centre Breast Cancer Study CNIO-BCS Spain
California Teachers Study CTS USA
ESTHER Breast Cancer Study ESTHER Germany
ICR Familial Breast Cancer Study FBCS UK
German Consortium for Hereditary Breast & Ovarian Cancer GC-HBOC (GFBCS) Germany
Gene Environment Interaction and Breast Cancer in Germany GENICA Germany
Genetic Epidemiology Study of Breast Cancer by Age 50 GESBC Germany
Hannover Breast Cancer Study HABCS (HBCS) Germany
Helsinki Breast Cancer Study HEBCS Finland
Hannover-Minsk Breast Cancer Study HMBCS Belarus
Hannover-Ufa Breast Cancer Study HUBCS Russia
Karolinska Breast Cancer Study KARBAC Sweden
Kuopio Breast Cancer Project KBCP Finland
kConFab/AOCS kConFab/AOCS Australia
Leuven Multidisciplinary Breast Centre LMBC Belgium
Mammary Carcinoma Risk Factor Investigation MARIE Germany
Milan Breast Cancer Study Group MBCSG Italy
Mayo Clinic Breast Cancer Study MCBCS USA
Melbourne Collaborative Cohort Study MCCS Australia
Multi-ethnic Cohort MEC USA
Memorial Sloan-Kettering Cancer Center MSKCC USA
Mexican Case Control Study of Breast Cancer MXCCS Mexico
Malaysian Breast Cancer Genetic Study MYBRCA Malaysia
Norwegian Breast Cancer Study NBCS Norway
Northern California Breast Cancer Family Registry NC-BCFR USA
Nurses Health Study NHS USA
Nigerian Breast Cancer Study NGBCS Nigeria
Oulu Breast Cancer Study OBCS Finland
Ontario Familial Breast Cancer Registry OFBCR Canada
Leiden University Medical Centre Breast Cancer Study ORIGO (LUMCBCS) Netherlands
NCI Polish Breast Cancer Study PBCS Poland
Prospective Study of Outcomes in Sporadic Versus Hereditary Breast Cancer POSH UK
Rotterdam Breast Cancer Study RBCS Netherlands
Singapore and Sweden Breast Cancer Study SASBAC Sweden
Sheffield Breast Cancer Study SBCS UK
Study of Epidemiology and Risk factors in Cancer Heredity SEARCH UK
Seoul Breast Cancer Study SEBCS (SBCP) Korea
IHCC-Szczecin Breast Cancer Study SZBCS Poland
IARC-Thai Breast Cancer Study TBCS Thailand
Taiwanese Breast Cancer Study TWBCS Taiwan
UCI Breast Cancer Study UCIBCS USA
UK Breakthrough Generations Study UKBGS UK
US Three State Study US3SS USA
US Radiologic Technologists Study USRTS USA
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Gene / SNP Breast cancer risk BCAC manuscript
CASP8 D302H CG v. GG: OR 0.89, 95% CI 0.85-0.94
CC v. GT: OR 0.74, 95% CI 0.62-0.87
Cox et al., Nat Genet 2007
FGFR2, rs2981582
TNRC9, rs3803662
MAP3K1, rs889312
LSP, rs3817198
8q24, rs13281615
ORhom 1.63, 95% CI 1.53-1.72, p=4.1 × 10
-76
ORhom 1.39, 95% CI 1.25-1.45, p=1.4 × 10
-36
ORhom 1.27, 95% CI 1.19-1.36, p=4.1 × 10
-20
ORhom 1.17, 95% CI 1.08-1.25, p=4.1 × 10
-9
ORhom 1.18, 95% CI 1.10-1.25, p=4.1 × 10
-12
Easton et al., Nat Genet 2007
FGFR2, 2981582
8q24, 13281615
TNRC9, rs3803662
ER positive:p=10
-13
PGR positive: p=10
-5
low grade: p=10
-8
metastases: p=0.013
ER positive: p=0.001
PGR positive: p=0.011
low grade: p=10
-4
ER negative: OR 1.14, 95% CI 1.09-1.21
Garcia-Closas et al., PLoS Genet 2008
AKAP9 M463I TT v. GG:
OR 1.17, 95% CI 1.08-1.27, p=0.0003
familial cases: OR 1.27, 95% CI 1.12-1.45, p=0.0003
TT v. GT:
OR 1.10, 95% CI 1.04-1.17, p=0.001
familial cases: OR 1.16, 95% CI 1.06-1.27, p=0.001
Frank et al., JNCI 2008
3p24, rs4973768
17q23, rs6504950
ORper-allele 1.11, 95% CI 1.08-1.13, p=4.1 × 10
-23
ORper-allele 0.95, 95% CI 0.92-0.97, p=1.4 × 10
-8
Ahmed et al., Nat Genet 2009
2q35, rs13387042 OR per-allele 1.12, 95% CI 1.09 -1.15; ptrend 1.0 × 10
-19 (European Caucasian)
ER positive: OR 1.14, 95% CI 1.10-1.17; p=10
-15
ER negative: OR 1.10, 95% CI 1.04-1.15; p=0.0003
PGR positive: OR 1.15, 95% CI 1.11-1.19; p=5 × 10
-14
PGR negative: OR 1.10, 95% CI 1.06-1.15; p=0.00002
Milane et al., JNCI 2009
Table 3 Centers collaborating in CIMBA
Study Acronym Country
Breast Cancer Family Registry BCFR USA/Australia
Baltic Familial Breast Ovarian Cancer Consortium BFBOCC Latvia/Lithuania
BRCA-gene mutations and breast cancer in South African women BMBSA South Africa
Rigshospitalet CBCS Denmark
Spanish National Cancer Centre CNIO Spain
CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella CONSIT TEAM Italy
German Cancer Research Center DKFZ Germany
Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland DNA HEBON Netherlands
Epidemiological Study of Familial Breast Cancer EMBRACE UK
Fox Chase Cancer Center FCCC USA
German Familial Breast Group GC-HBOC Germany
Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers GEMO France/Greece/USA
Georgetown University GEORGETOWN USA
Gynecologic Oncology Group GOG USA
Hospital Clinico San Carlos HCSC Spain
Helsinki Breast Cancer Study HEBCS Finland
Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia HRBCP Hong Kong
Molecular Genetic Studies of Breast- and Ovarian Cancer in Hungary HUNBOCS Hungary
Institut Català d’Oncologia ICO Spain
International Hereditary Cancer Centre IHCC Poland
Iceland Landspitali - University Hospital ILUH Iceland
INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility INHERIT Canada
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Istituto Oncologico Veneto IOVHBOCS Italy
Kathleen Cuningham Consortium for Research into Familial Breast Cancer KCONFAB Australia/New Zealand
Korean Hereditary Breast Cancer Study KOHBRA Korea
Modifiers and Genetics in Cancer MAGIC USA
Mayo Clinic MAYO USA
Modifier Study of Quantitative Effects on Disease MOD SQUAD USA
Memorial Sloane Kettering Cancer Center MSKCC USA
General Hospital Vienna MUV Austria
National Cancer Institute NCI USA
National Israeli Cancer Control Center NICCC Israel
N.N. Petrov Institute of Oncology NNPIO Russia
Ontario Cancer Genetics Network OCGN Canada
The Ohio State University Comprehensive Cancer Center OSU CCG USA
Odense University Hospital OUH Denmark
Università di Pisa PBCS Italy
South East Asian Breast Cancer Association Study SEABASS Malaysia/Singapore
Sheba Medical Centre SMC Israel
Swedish Breast Cancer Study SWE-BRCA Sweden
University of California Irvine UCI USA
University of California San Francisco UCSF USA
UK and Gilda Radner Familial Ovarian Cancer Registries UKGRFOCR UK/USA
University of Pennsylvania UPENN USA
Cedars-Sinai Medical Center WCRI USA
Table 4 SNPs associated with breast cancer risk in BRCA1/2 carriers
Gene / SNP Breast cancer risk CIMBA manuscript
RAD51, rs11683487 BRCA2: HRhom 3.18, 95% CI 1.39-7.27, p=0.0007 Antoniou et al. AJHG 2007
TNRC9, rs3803662
FGFR2, rs2981582
MAP3K1, rs889312
BRCA1/2: HR 1.13, 95% CI: 1.06-1.20, ptrend=5×1 0
-5
BRCA2: HR 1.32, 95% CI: 1.20-1.45, ptrend=1.7 × 10
-8
BRCA2: HR 1.12, 95% CI: 1.02-1.24, ptrend=0.02
Antoniou et al. AJHG 2008
2q35, rs13387042
LSP1, rs3817198
2q35, rs13387042
BRCA1: HR 1.14, 95% CI: 1.04-1.25, p=0.0047
BRCA2: HR 1.16, 95% CI: 1.07-1.25, ptrend=2.8 × 10
-4
HR 1.18 95% CI: 1.04-1.33, p=0.0079
Antoniou et al. Hum Mol Genet 2008
Table 5 Centers collaborating in OCAC
Name Acronym OCAC Acronym Country
Australian Ovarian Cancer Study and Australian Cancer Study (Ovarian Cancer) AOCS/ACS AUS Australia
Bavarian Ovarian Cancer Cases and Controls BOCC BAV Germany
Belgian Ovarian Cancer Study BELOCS BEL Belgium
Connecticut Ovary Study (none) CON USA
Diseases of the Ovary and their Evaluation Study DOVE DOV USA
German Ovarian Cancer Study GOCS GER Germany
Hawaii Ovarian Cancer Study (none) HAW USA
Hannover-Jena Ovarian Cancer Study HJOCS HJO Germany
Hannover-Minsk Ovarian Cancer Study HMOCS HMO Germany
Helsinki Ovarian Cancer Study HOCS HOC Finland
Hormones and Ovarian Cancer Prediction HOPE HOP USA
Polish Ovarian Cancer Study POCS JAC Poland
Women’s Cancer Research Institute (Cedars-Sinai Medical Center) WCRI LAX USA
The Danish Malignant Ovarian Tumour Study MALOVA MAL Denmark
Mayo Clinic Ovarian Cancer Case Control Study (none) MAY USA
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Table 5 Centers collaborating in OCAC (Continued)
Melbourne Collaborative Cohort Study MCCS MCC Australia
Memorial Sloan Kettering Cancer Center Gynecology Tissue Bank MSKGTB MSK USA
North Carolina Ovarian Cancer Study NCOCS NCO USA
New England-based Case-Control Study of Ovarian Cancer NECC NEC USA
Nurses Health Study NHS NHS USA
New Jersey Ovarian Cancer Study NJOCS NJO USA
Nijmegen Polygene Study & Nijmegen Biomedical Study POLYGENE NTH Netherlands
Prognostic Factors in Epithelial Ovarian Cancer EOC NTX Netherlands
Ovarian Cancer in Alberta and British Columbia Study OVAL-BC OVA Canada
NCI Ovarian Case-Control Study in Poland NCI-OCS POL Poland
Roswell Park Cancer Institute Cases RPCI RPX USA
UK SEARCH Ovarian Cancer Study SEARCH SEA UK
Southampton Ovarian Cancer Study (none) SOC UK
Genetic Epidemiology of Ovarian Cancer GEOCS STA USA
Tampa Bay Ovarian Cancer Study TBOCS TBO USA
Familial Ovarian Tumour Study FOTS TOR Canada
UC Irvine Ovarian Cancer Study (none) UCI USA
UK Ovarian Cancer Population Study UKOPS UKO UK
Los Angeles County Case-Control Studies of Ovarian Cancer LAC-CCOC USC USA
Table 6 SNPs associated with ovarian cancer risk
Gene / SNP Ovarian cancer risk OCAC manuscript
CDKN2A, rs3731257
CDKN1B, rs2066827
OR 0.91, 95% CI 0.85-0.98, p=0.008
OR 0.93, 95% CI 0.87-0.995, p=0.036
Gayther et al., Cancer Res 2007
TP53, 23 SNPs:
rs2287498
rs12951053
ORper-allele 1.30, 95% CI 1.07-1.57
ORper-allele 1.19, 95% CI 1.01-1.38
Schildkraut et al., Cancer Res 2009
NMI, rs11683487 OR 0.89, 95% CI 0.80-0.99, p=0.032 Quaye et al., BJC 2009
CYP3A4, rs2740574 ORhom 2.81, 95% CI 1.20-6.56, p=0.017 Pearce et al., BJC 2009
9p22.2, rs3814113 OR 0.82, 95% CI 0.79-0.86, p=5.1×10
-19
serous tumors: OR 0.77, 95% CI 0.73-0.81, p=4.1×10
-21
Song et al., Nat Genet 2009
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